We recently published a list of 15 Best Large-Cap Value Stocks to Buy as the Recession Hits. In this article, we are going to ...

U.S. Food and Drug Administration Commissioner Martin Makary announced on Thursday a policy to limit employees of companies ...

The stock's rise snapped a three-day losing streak.

Guggenheim analyst Vamil Divan maintained a Buy rating on Merck & Company (MRK – Research Report) today and set a price target of ...

Shares of Merck & Co. Inc. MRK slid 2.46% to $76.46 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and ...

In the first meeting of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

Mural Oncology plc said on Tuesday it would stop clinical development of its lead cancer treatment, nemvaleukin, and look ...

Initiation by Merck of a Phase 2 trial in Alzheimer’s disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company’s ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s ...

Summit Therapeutics is making strides with ivonescimab, but upcoming trial results and financial challenges suggest caution.